Assay News and Research

RSS

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin.

23 Mar 2012

MD Anderson, Transgenomic partner to evaluate use of ICE COLD-PCR

Transgenomic, Inc. today announced that it has begun a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the Company's very high sensitivity ICE COLD-PCR mutation detection technology in analysis of DNA isolated from circulating tumor cells (CTCs) in blood samples from patients with advanced cancer.

21 Mar 2012

FDA, Agilent partner to develop new tools for detection of salmonella subtypes

Agilent Technologies Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the U.S. Food and Drug Administration to develop new tools to detect and analyze pathogens in food.

20 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012

Publicly available profile of effects of approved and investigational medicines

The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today.

14 Mar 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012

Abbott, GenLab collaborate to develop new assay for PLEX-ID automated microbial identification system

Abbott announced today it will collaborate with Genetics Laboratory, Inc. on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopedic infections.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

Berg Diagnostics achieves CLIA certificate of accreditation

Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA).

2 Mar 2012

Study offers hope for novel approach to prevent AD

As scientists struggle to find an effective way to prevent Alzheimer's disease, researchers at the University of Wisconsin-Madison may have found a new approach to interrupting the process that leads to the devastating disease.

2 Mar 2012

Positive results from Critical Diagnostics' biomarker study in ambulatory heart failure patients

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model.

29 Feb 2012

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012

Insight into relationship between two types of suppressors in cancerous tumors

The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.

23 Feb 2012

Allergan's cell-based assay for botulinum toxin type A products receives positive opinions

Allergan is pleased to announce the company has received two positive opinions regarding its fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX and VISTABEL (Allergan's botulinum toxin type A products).

23 Feb 2012

China's SFDA approves Dynex DS2 ELISA analyzer

Dynex Technologies announced today it has received approval from China's State Food and Drug Administration (SFDA) to market the DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China.

From Thermo Fisher Scientific Inc. 22 Feb 2012

NYSDOH approves Enzo Biochem's ColonSentry test

Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.

22 Feb 2012

Insulin production may persist for decades after onset of type 1 diabetes

Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.

22 Feb 2012

DANSR/FORTE assay more effective in diagnosing Edwards and Down syndrome

Using a noninvasive test on maternal blood that deploys a novel biochemical assay and a new algorithm for analysis, scientists can detect, with a high degree of accuracy, the risk that a fetus has the chromosomal abnormalities that cause Down syndrome and a genetic disorder known as Edwards syndrome.

22 Feb 2012